COVID19 Long Term Effects in Patients Treated with Chlorine Dioxide

Abstract

The coronavirus disease 2019 (COVID19) has generated widespread healthcare concerns and has overburdened healthcare institutions. As the number of COVID19 patients recovers, so does the frequency of reports of COVID19-like symptoms following discharge. A telephone survey with standardized questions was undertaken in which participants were asked if they had had any of 25 possible sequelae after being diagnosed with COVID19 and treated with a Chlorine Dioxide Solution (CDS). One hundred sixty-one people completed the survey. We discovered that rising age is a risk factor (OR = 1.035, p = 0.028, 95% CI = 1.004-1.069), and the odds of having any symptoms in moderate patients is 0.077 compared to mild patients (P = 0.003). It was predicted that 64.6 percent of patients treated with CDS for SARS-CoV-2 infection experienced an average of 3.41 long-term effects. There were no variations in the number of sequelae reported by sex, age, COVID19 severity, or therapy method. The five most prevalent manifestations of the 25 distinct long-term symptoms observed in this study were fatigue, hair loss, dyspnea, concentration problem, and sleep difficulties. In addition, individuals treated with multiple drugs (COVID19 conventional treatment plus a CDS) had 2.7 fewer cases of sequelae, and patients treated exclusively with CDS had 6.14 fewer incidences of long-term effects. People who get a CDS are 19% less likely to experience long-term health effects than patients who receive standard COVID19 therapy. According to the findings of this study, patients who receive a CDS have a reduced probability of developing sequelae. Furthermore, the incidence of long-term effects is lower in individuals treated exclusively with a CDS. The recent findings involving Chlorine Dioxide support the development of clinical studies to evaluate its efficacy in preventing the development of COVID19 long-term effects.